Participated · Series B · May 2022

Aspen Neuroscience is pioneering personalized regenerative medicine by converting a patient’s own skin cells into induced pluripotent stem cells and then into dopaminergic neuronal precursor cells to treat neurodegenerative diseases. Its lead candidate, ANPD001, is the most advanced autologous cell therapy in the U.S. for moderate to advanced Parkinson’s disease and has received FDA Fast Track designation. The company’s proprietary manufacturing platform integrates machine-learning-based genomic testing for rigorous quality control and scalability, and it includes a precision MRI-guided delivery device for minimally invasive transplantation. Recent clinical progress includes initiation of Cohort 3 in a Phase 1/2a trial, with earlier cohorts showing favorable safety and clinician- and patient-reported improvements without the need for immunosuppression. Aspen plans to expand its pipeline to additional neurological indications while scaling manufacturing to meet future commercial demand. Headquartered in San Diego, the private company has raised more than $340 million to date, including an $8 million grant from the California Institute for Regenerative Medicine.

Participated · Series C · Feb 2022

Dewpoint Therapeutics develops first-in-class condensate‑modulating small molecules (c‑mods) to target previously intractable biology. Its lead program, DPTX3186, is an orally delivered c‑mod designed to selectively disrupt oncogenic Wnt/β‑catenin signaling and is being advanced into clinical trials. The company also plans to accelerate a c‑mod program targeting MYC. Dewpoint’s platform is AI/ML‑powered and supports a pipeline across oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. It maintains collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma to help translate condensate biology into medicine. The Series D financing extends operational runway into early 2027 and supports clinical proof‑of‑concept goals for DPTX3186 in gastric cancer by the end of 2026. Dewpoint Therapeutics applies the emerging understanding of biomolecular condensates to drug discovery, operating a fully integrated, multi-component biology platform and an AI-driven data science platform. The company advances a pipeline of over 20 discovery and development programs spanning oncology, neuromuscular, cardiopulmonary, and virology indications. Proceeds from its recent financing will fund advancement of multiple programs through IND and further investment in platform and data science capabilities. Dewpoint also plans to expand research infrastructure to support its growing pipeline. The company is led by CEO Ameet Nathwani and has scientific teams in Boston, Dresden, and Berlin. It is headquartered in Boston, MA. Dewpoint Therapeutics applies emerging biomolecular condensate biology to drug discovery through a proprietary, high‑throughput platform that detects and modulates condensate behavior. The platform tests libraries of potential drugs to identify compounds that dissolve, form, stabilize, change composition of, or selectively deliver payloads into condensates. Dewpoint plans to use proceeds from its recent financing to further develop the platform and identify additional condensate‑modulating compounds. The company has announced collaborations with Merck (for an HIV program) and Bayer (for cardiovascular and gynecological programs) and is exploring opportunities in oncology, neurodegeneration, metabolic disease, and immunology. Dewpoint’s team includes researchers and executives who have collectively brought more than ten drugs to market, and its scientific founders include Tony Hyman and Rick Young. The company operates research teams in Boston, Dresden, and Berlin. Dewpoint Therapeutics is building a proprietary platform to drug biomolecular condensates, membrane-less cellular compartments that have been difficult to analyze with traditional drug‑discovery methods. The company leverages recent insights from founders Anthony Hyman and Richard Young and an interdisciplinary mix of soft matter physics, biophysics, computation, and biology to enable new therapeutic approaches. Leadership includes CEO Amir Nashat and Chief Scientific Officer Mark Murcko, and the company has assembled a broad scientific advisory board chaired by MIT’s Phillip Sharp. Dewpoint is industrializing condensate-directed discovery by building teams in Cambridge, MA and Dresden, Germany. Target disease areas called out by the company include cancer, neurodegenerative disorders, immunology, cardiovascular disease, women’s health, and virology. The company launched with a $60 million Series A to advance its platform and progress programs toward therapeutic discovery.

Participated · Equity · Nov 2021

Shoreline Biosciences is developing intelligently designed, off-the-shelf induced pluripotent stem cell (iPSC)-derived NK and macrophage cellular immunotherapies. The company focuses on standardized, targeted cell products including next-generation, more persistent iPSC-derived NK cells and macrophage-cell therapies. Shoreline is advancing proprietary iPSC differentiation methods, genetic reprogramming of disease-relevant pathways, and plans to create NK-specific CARs, switchable CAR-NK engagers, and macrophage-specific CARs. It targets both hematologic malignancies and solid tumors and has established strategic partnerships with Kite (a Gilead Company) and BeiGene. Shoreline also reports contract development and manufacturing organization (CDMO) partnerships to support manufacturing. The company is headquartered in San Diego, CA and is well-capitalized to continue pipeline advancement. Shoreline Biosciences is developing intelligently designed allogeneic, off-the-shelf natural killer (NK) and macrophage cellular immunotherapies derived from induced pluripotent stem cells (iPSC). The company focuses on standardized and targeted NK- and macrophage-based cell therapies for cancer and other serious diseases. It plans to use new funding to accelerate advancement of its proprietary iPSC platform and next-generation NK and macrophage cell therapy programs. Research efforts supported by the financing include work to create potent and persistent NK cell-specific chimeric antigen receptors (CARs), switchable CAR-NK cell engagers, and macrophage-specific CARs. Shoreline has entered a strategic relationship with the Advanced Cell Therapy Laboratory of UC San Diego to secure GMP manufacturing of its cell therapy products. The company was co-founded by Dan Kaufman, M.D., Ph.D., along with Steven Holtzman, William Sandborn, M.D., and Kleanthis G. Xanthopoulos, Ph.D.

Participated · Series B · Oct 2021

ReCode Therapeutics is a clinical-stage biotech developing genetic medicines for cystic fibrosis, leveraging its Selective Organ Targeting lipid nanoparticle delivery platform alongside mRNA and gene-editing approaches. Its lead inhaled program, RCT2100, is in a fully enrolled Phase 2a study and received Fast Track designation from the U.S. FDA in February 2026, with data expected in the fourth quarter. The company has entered a research collaboration with an undisclosed gene-editing company to co-develop therapies that correct CFTR mutations, combining ReCode's delivery technology with the partner's editing platform. The collaboration and funding from the Cystic Fibrosis Foundation are intended to advance one or more candidates toward clinical development and commercialization. Recent leadership changes include Heather Clark being named CEO and former CEO Shehnaaz Suliman becoming executive chair of the board. Clark joined ReCode in 2022 and has extensive rare-disease and cystic fibrosis drug development experience, including more than two decades at Vertex Pharmaceuticals.

Participated · Series B · Aug 2021

Immunitas Therapeutics is a Waltham, MA-based therapeutics company that uses a single cell genomics platform to identify and validate immune targets in parallel with antibody discovery and engineering. The company is advancing multiple programs derived from its platform, including lead asset IMT-009, a first-in-class CD161 inhibitor modulating NK and T cells, and IMT-073, a dual-target NK and T cell modulator. Immunitas intends to use the new funds to advance IMT-009 into the clinic for both solid tumors and hematological malignancies. The company is led by CEO Jeffrey Goldberg and recently appointed Amanda Wagner as Chief Business Officer. Since its 2019 founding, Immunitas has raised a total of $97 million in venture funding from a syndicate of strategic and life-sciences investors. Immunitas employs a single cell genomics-based platform to dissect the tumor microenvironment and identify novel immune targets from human samples. The company has generated fully humanized monoclonal antibodies with single-agent activity in preclinical oncology models. Immunitas plans to advance its lead programs into human efficacy studies and clinical trials, driven by specific clinical biomarkers derived from its platform. The company was founded by Longwood Fund and is presented from Boston. Its scientific founders and leaders include pioneers in tumor immunobiology who contributed to the platform and target discovery. Immunitas intends to use its approach to accelerate translation of human biology into candidate therapeutics and patient-selection biomarkers.